Originally aired June 20, 2014: Bionic Pancreas in Type 1 Diabetes and Weekly Dalbavancin for Skin Infections
Travis and Amol want you to:
1. Understand the potential role of a novel bionic pancreas in glycemic control in type 1 diabetes.
2. Recognize that dalbavancin is non-inferior to vancomycin/linezolid in treating skin infections and represents a potentially revolutionary once weekly approach to treating serious infections.
Continuing Medical Education
Internists can receive 0.5 hours of Continuing Medical Education credit for each podcast they listen to through the Canadian Society of Internal Medicine (MOC Category 1) and the American Medical Association (PRA Category 1). To receive CME credit for listening to this podcast, please click here to fill out our Evaluation and Impact Assessment Form.
A picture of the bionic pancreas can be seen in the supplementary materials here.